Clinical trials: Advanced Malignant Tumor
Advanced Cancer, Solid Tumor
Randomized Controlled Trial of Integrated Early Palliative Care
This study verifies whether integrated Early Palliative Care for advanced cancer patients diagnosed due to a solid tumor improve quality of life and enhances the ability to overcome the current crisis.
- Trial name
- NCT03181854
- Testing
- Telephone coaching, Consultation with PCT doctor
- Where
- 10 sites in South Korea
- Volunteers
- 144 people
- Sponsor
- Seoul National University Hospital
Solid Tumor
A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors
This is a Phase 1 dose-escalation and expansion study that will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of SAIL66 in patients with CLDN6-positive locally advanced…
- Trial name
- NCT05735366
- Testing
- SAIL66
- Where
- 9 sites in United States, Japan
- Volunteers
- 22 people
- Sponsor
- Chugai Pharmaceutical
Advanced Solid Tumors, Gastric Cancer
PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors
The purpose of this study is to assess the safety and effects of PF-07265028 as monotherapy and in combination with sasanlimab. The study aims to identify the maximum tolerated dose (MTD) of PF-07265028 as monotherapy; evaluate…
- Conditions
- Advanced Solid Tumors, Gastric Cancer, Gastroesophageal Junction Cancer, Urothelial Cancer
- Trial name
- NCT05233436
- Testing
- PF-07265028, Sasanlimab
- Where
- 8 sites in United States, Japan
- Volunteers
- 21 people
- Sponsor
- Pfizer
Breast Cancer Metastatic
Efficacy of High Dose Tamoxifen to Advanced Hormone Receptor-High Expressed Breast Cancer
Background: Endocrine therapy is an effective and safe treatment for hormone receptor positive breast cancer. Unfortunately , endocrine treatment resistance occurs and there is an urgent need for treatment alternative.
- Trial name
- NCT03045653
- Testing
- Tamoxifen Oral Product
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Soft Tissue and Bone Tumor, Head and Neck Cancer
Radiotherapy Concurrent With Apatinib in Advanced Soft Tissue and Bone Sarcomas of Head and Neck--RASS Study
This is a non-randomized, phase II, open label study of radiotherapy concurrent with Apatinib Mesylate after surgery in patients with advanced head and neck soft tissue and bone sarcomas.
- Conditions
- Soft Tissue and Bone Tumor, Head and Neck Cancer, Sarcoma
- Trial name
- RASS (NCT03539172)
- Testing
- Apatinib Mesylate
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Advanced Malignant Cancer
A Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3019 Capsule in Subjects With Advanced Malignant Tumors
The trial was divided into two phases: dose escalation and dose expansion. The dosing regimens were single-dose study and continuous dosing study.
- Trial name
- NCT06943677
- Testing
- TQB3019 capsules
- Where
- 15 sites in China
- Volunteers
- 80 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Neoplasms
Study Evaluating Intravenous CMD-193 in Subjects With Advanced Malignant Solid Tumors
The primary purpose of this study is to evaluate the safety, tolerability, and maximum tolerated dose (MTD) of CMD-193 administered intravenously (IV) to subjects with advanced malignant tumors.
- Trial name
- NCT00257881
- Testing
- CMD-193
- Where
- 2 sites in Japan
- Volunteers
- 46 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Solid Tumor, Solid Tumor, Adult
Psychotherapy Intervention for Latinos With Adv Cancer
The purpose of this study is to adapt a counseling intervention called Meaning Centered Psychotherapy to make it culturally relevant for Latinos. Cancer affects patients and their loved ones.
- Conditions
- Solid Tumor, Solid Tumor, Adult, Solid Tumor, Unspecified, Adult
- Trial name
- NCT04537936
- Testing
- Meaning Centered Psychotherapy for Latinos, Functional Assessment of Cancer Therapy - Spiritual Well-Being Scale, Meaning Centered Psychotherapy for Latinos for Waitlist Control Patients
- Where
- 4 sites in United States, Puerto Rico
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Anal Squamous Cell Carcinoma, Colorectal Neoplasms
Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers
REFIT-MSS is a non-randomized, multicenter, open-label, multi-cohort, 2-stage, phase II trial to evaluate the efficacy and safety of regorafenib in combination with tislelizumab (referred as Rego-Tisle) in adult patients with…
- Conditions
- Anal Squamous Cell Carcinoma, Colorectal Neoplasms, Soft Tissue Sarcoma, Malignant Pleural Mesothelioma
- Trial name
- REFIT-MSS (NCT05582031)
- Testing
- Regorafenib in combination with Tislelizumab
- Sponsor
- Translational Research in Oncology
Advanced or Metastatic Solid Tumors
A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors
This is an open-label, dose escalation and dose expansion study of MDK-703 as a monotherapy and in combination with other cancer therapies in adult study participants with advanced or metastatic solid tumors.
- Trial name
- ORCHID-1 (NCT05716295)
- Testing
- MDK-703, Checkpoint Inhibitor, Immune
- Where
- 6 sites in United States
- Volunteers
- 26 people
- Sponsor
- Medikine, Inc.
Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion
An Observational Study to Learn More About NTRK Gene Fusion Positive in Solid Tumor in Japan
This is an observational study in which data from the past of people with solid tumors harboring an NTRK gene fusion in Japan are studied.
- Trial name
- NCT05793281
- Testing
- No Drug
- Where
- Japan
- Volunteers
- 46,621 people
- Sponsor
- Bayer
Pancreatic Neuroendocrine Tumor
A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor
A Phase II Randomized,Controlled,Open Label,Multicentre Study to evaluate the efficacy and safety of Tegafur combined with Temozolomide versus Tegafur combined with Temozolomide and Thalidomide in subjects with Advanced…
- Trial name
- NCT03204019
- Testing
- Tegafur and Temozolomide, Tegafur and Temozolomide combined with Thalidomide
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chinese Academy of Medical Sciences
Head and Neck Cancer
Stereotactic Radiosurgery in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer
RATIONALE: Stereotactic radiosurgery may be able to send x-rays directly to the tumor and cause less damage to normal tissue. PURPOSE: This phase I trial is studying the side effects of stereotactic radiosurgery in treating…
- Trial name
- NCT00851253
- Testing
- stereotactic radiosurgery
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Boston Medical Center
Advanced NSCLC, Advanced Endometrial Cancer
A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor
This study is a multicenter, two-tumor, multi-cohort, dose-escalation and dose-expansion Phase Ib/II clinical trial of HB0025 combined with chemotherapy, consists of two phases: the dose escalation phase (Ib) and the dose…
- Trial name
- NCT06758557
- Testing
- HB0025, Pemetrexed, Paclitaxel
- Where
- 14 sites in China
- Volunteers
- 282 people
- Sponsor
- Huabo Biopharm Co., Ltd.
Breast Cancer, Cholangiocarcinoma
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion.
- Conditions
- Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms
- Trial name
- STARTRK-2 (NCT02568267)
- Testing
- Entrectinib
- Where
- 120 sites in United States, Australia and 14 more
- Volunteers
- 534 people
- Sponsor
- Hoffmann-La Roche
GIST, Metastatic Disease
Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
Patients with advanced GIST are treated with imatinib. This study seeks to look at a new therapeutic agent at the time of tumor progression following treatment with 600-800 mg daily of imatinib.
- Trial name
- NCT01089595
- Testing
- Nilotinib, Nilotinib with Imatinib
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Fox Chase Cancer Center
Liver Cancer, Lung Cancer
Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors
Tumor infiltration lymphocytes (TILs) have been harvested from advanced cancer patients and constructed to knockout PD1 gene and express scFvs against both PD1 and CTALA4 and CARs against various antigens, followed by transfusion…
- Conditions
- Liver Cancer, Lung Cancer, Breast Cancer, Colo-rectal Cancer
- Trial name
- NCT04842812
- Testing
- TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, or B7-H3
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Melanoma
CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma
The purpose of this study is to see whether the combination of low-dose Cyclophosphamide and Anti-CTLA4 (Ipilimumab) will stop tumor growth in patients with advanced skin cancer.
- Trial name
- NCT01740401
- Testing
- Cyclophosphamide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers
In this clinical phase I, non-randomized, open-label, uncontrolled, interventional, multi-center trial, 20 adult subjects (≥ 18 years of age) with advanced non-melanoma skin cancers will receive a fixed dose of 0.1 mg of…
- Conditions
- Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Non-Melanoma Skin Cancers
- Trial name
- NCT04160065
- Testing
- IFx-Hu2.0
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- TuHURA Biosciences, Inc.
Advanced Solid Tumor
The Safety, Tolerability, and Initial Efficacy of HX009 in Patients With Advanced Malignancies
This is a first-in-human, multicenter, open-label, multiple-dose Phase I study to investigate the safety, tolerability, and initial efficacy of HX009 in subjects with advanced malignant tumors.
- Trial name
- NCT04097769
- Testing
- HX009
- Where
- Australia
- Volunteers
- 21 people
- Sponsor
- Waterstone Hanxbio Pty Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.